Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Opinion & Analysis Soligenix Inc SNGX

Healthcare Biotechnology
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics segment is developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe... see more

Opinion & Analysis (NDAQ:SNGX)

    'Data Readouts Approaching in Two Pivotal Trials' for Biopharma Targeting Unmet Needs

    Streetwise Reports August 22, 2019

    NIH Selects Biopharma's Lead Asset for Commercialization Accelerator Program

    Streetwise Reports September 27, 2018

    Soligenix's diversified pipeline advances on all fronts

    The Life Sciences Report August 31, 2016

    VIDEO: Focused on Rare Disease Therapies

    BTV-Business Television June 28, 2016

    Soligenix develops defenses against bioterrorism SNGX

    The Life Sciences Report June 15, 2016

    Soligenix fosters potent pipeline of orphan disease compounds in areas of unmet medical need

    The Life Sciences Report April 27, 2016